Abstract |
In order to evaluate the significance of thyrotropin-
binding inhibiting immunoglobulin (TBII) in the
patients with autoimmune thyroid diseases, the authors
investigated 402 cases of Graves' disease and 230 cases
of Hashimoto's thyroiditis comparing 30 cases of normal
healthy adult at Kyung Pook University Hospital from
February 1993 to August 1994. The TBII was tested by
radioimmunoassay and assesed on the dynamic change with
the disesase course, thyroid functional parameters, and
other thyroid autoantibodies; antithyroglobulin
antibody(ATAb) and antimicrosomal antibody(AMAb)
including thyroglobulin. The serum level of TBII was
40.82±21.651(mean±SD)% in hyperthyroid Graves'
disease and 8.89±14.522% in Hashimoto's thyroiditis
and both were significant different from normal control
of which was 3.21±2.571%. The frequency of abnormally
increased TBII level was 92.2% in hyperthyroid Craves'
disease, 46.7% in euthyroid Graves' disease or
remission state of hyperthyroidism, and 23.9% in
Hashimoto's thyroiditis. The serum levels of increased
TBII in Graves' disease were positively correlated with
RAIU, serum T3, T4, and FT4, but negatively correlated
with serum TSH(each p〈0.001). The TBII in Graves'
disease had significant positive correlation with serum
thyroglobulin and AMAb, but no significant correlation
with ATAb. In the Hashimoto's thyroiditis, the serum
levels of TBII were positively correlated with RAIU,
serum T3, TSH and AMAb, but not significantly
correlated with serum T4, FT4, thyroglobulin and ATAb.
Therefore serum level of TBII seemed to be a useful
mean of assessing the degree of hyperthyroidism in
Graves' disease and correlated well with thyroidal
stimulation. The serum level of TBII in Hashimoto's
thyroiditis is meaningful for the degree of both
functionl abnormality reflecting either hyperfunction
or hypofunction and the immunologic abnormality. |